NASDAQ$MIRM
Mirum Pharmaceuticals Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Mirum Pharmaceuticals reported fourth quarter and year-end 2023 financial results.
Mirum Pharmaceuticals reported net product sales of $178.9 million for the full year 2023, representing 142% growth over 2022.
- Net product sales totaled $178.9 million, and full year 2023 revenue totaled $186.4 million, delivering 142% growth over 2022 total revenue.
- 2023 LIVMARLI net product sales totaled $141.8 million, representing approximately 89% growth over 2022 net product sales.
- International business grew to 18 countries with reimbursed access to LIVMARLI.
- FDA Prescription Drug User Free Act (PDUFA) date for LIVMARLI in progressive familial intrahepatic cholestasis (PFIC) is March 13, 2024.
Headline financials
Revenue & EPS history
Mirum Pharmaceuticals · Revenue · Quarterly
$69.6M
Revenue by segment
Mirum Pharmaceuticals · $29.1M total across 1 segment · Q1 2023
- Net Product Sales$29.1M—100.0%
Forward guidance
Mirum Pharmaceuticals expects continued revenue growth across all approved medicines in 2024 with expected global net product sales of $310 million to $320 million.
Tailwinds
- Continued revenue growth across all approved medicines is expected in 2024.
- Expected global net product sales of $310 million to $320 million in 2024.
- LIVMARLI PFIC PDUFA date on track for March 13, 2024.
- New Drug Application (NDA) submission for CHENODAL in CTX planned in first half 2024.
- Volixibat VISTAS and VANTAGE interim analyses expected in first half of 2024
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+1.7%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+2.9%
Avg return
30 days after
59%
16 / 27 earnings
Positive
+26.4%
Q2 2022
Best reaction
-16.2%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.0% | +0.2% | -11.7% | |
| Q4 2025 | -15.1% | -19.2% | -18.6% | |
| Q3 2025 | -1.4% | -1.8% | -3.5% | |
| Q1 2025 | +9.9% | +9.8% | +12.5% | |
| Q4 2024 | -7.0% | -10.5% | -9.0% | |
| Q3 2024 | +5.6% | +6.9% | +1.6% | |
| Q2 2024 | +1.8% | +14.3% | +5.0% | |
| Q1 2024 | -0.3% | -4.4% | -3.2% | |
| Q4 2023 | -3.0% | -3.1% | -15.2% | |
| Q3 2023 | +5.6% | +5.6% | +12.6% | |
| Q2 2023 | +6.1% | +2.1% | +6.1% | |
| Q1 2023 | -8.3% | -7.9% | -7.9% | |
| Q4 2022 | -1.1% | -4.7% | +5.1% | |
| Q3 2022 | -16.2% | -19.7% | -24.1% | |
| Q2 2022 | +26.4% | +18.0% | +7.4% | |
| Q1 2022 | +7.1% | -4.4% | +7.0% | |
| Q4 2021 | +3.3% | +1.5% | +29.5% | |
| Q3 2021 | +0.1% | -1.2% | -7.9% | |
| Q2 2021 | +0.5% | -4.0% | +23.0% | |
| Q1 2021 | -1.4% | -6.3% | -10.8% | |
| Q4 2020 | +6.0% | +14.3% | +10.2% | |
| Q3 2020 | +11.6% | +16.9% | +48.0% | |
| Q2 2020 | +13.0% | +15.3% | -4.3% | |
| Q1 2020 | +0.1% | +6.2% | +10.8% | |
| Q4 2019 | +8.1% | -10.5% | +25.7% | |
| Q3 2019 | -0.1% | +4.0% | +22.6% | |
| Q2 2019 | -9.0% | -10.3% | -31.5% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro